TRANSCODE THERAPEUTICS, INC. Stock-Based Compensation
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Stock-Based Compensation of $485.43 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $61.87K, a 63.34% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $134.32K, a 34.31% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $131.51K, a 88.50% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $157.73K, a 13.88% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $485.43K, a 71.45% decline from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $1.70M, a 63.95% increase from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.04M, a 162.29% increase from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $395.33K, a 112.55% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $61.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $196.19K derived: sum of 2 quarters · filed 2026-04-15 | $327.70K derived: sum of 3 quarters · filed 2026-08-14 | $485.43K 10-K · filed 2026-04-15 |
| 2025-09-30 | $134.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $265.83K derived: sum of 2 quarters · filed 2026-08-14 | $423.56K 10-Q · filed 2025-11-14 | $592.33K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $131.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $289.24K 10-Q · filed 2026-08-14 | $458.01K derived: sum of 3 quarters · filed 2026-08-14 | $662.49K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $157.73K 10-Q · filed 2026-05-15 | $326.50K derived: sum of 2 quarters · filed 2026-05-15 | $530.98K derived: sum of 3 quarters · filed 2026-05-15 | $1.67M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $168.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $373.25K derived: sum of 2 quarters · filed 2026-04-15 | $1.52M derived: sum of 3 quarters · filed 2026-04-15 | $1.70M 10-K · filed 2026-04-15 |
| 2024-09-30 | $204.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.35M derived: sum of 2 quarters · filed 2025-11-14 | $1.53M 10-Q · filed 2025-11-14 | $1.84M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.33M 10-Q · filed 2025-08-14 | $1.64M derived: sum of 3 quarters · filed 2025-08-14 | $2.03M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $183.15K 10-Q · filed 2025-05-14 | $493.47K derived: sum of 2 quarters · filed 2025-05-14 | $885.80K derived: sum of 3 quarters · filed 2025-05-14 | $1.06M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $310.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $702.64K derived: sum of 2 quarters · filed 2025-04-15 | $878.13K derived: sum of 3 quarters · filed 2025-04-15 | $1.04M 10-K · filed 2025-04-15 |
| 2023-09-30 | $392.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $567.82K derived: sum of 2 quarters · filed 2024-11-14 | $726.58K 10-Q · filed 2024-11-14 | $857.13K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $175.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $334.24K 10-Q · filed 2024-08-14 | $464.80K derived: sum of 3 quarters · filed 2024-08-14 | $570.40K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $158.76K 10-Q · filed 2024-05-15 | $289.31K derived: sum of 2 quarters · filed 2024-05-15 | $394.92K derived: sum of 3 quarters · filed 2024-05-15 | $493.52K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $130.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $236.16K derived: sum of 2 quarters · filed 2024-04-01 | $334.76K derived: sum of 3 quarters · filed 2024-04-01 | $395.33K 10-K · filed 2024-04-01 |
| 2022-09-30 | $105.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $204.20K derived: sum of 2 quarters · filed 2023-11-14 | $264.77K 10-Q · filed 2023-11-14 | $303.77K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $98.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $159.17K 10-Q · filed 2023-08-14 | $198.17K derived: sum of 3 quarters · filed 2023-08-14 | $262.22K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $60.57K 10-Q · filed 2023-05-15 | $99.57K derived: sum of 2 quarters · filed 2023-05-15 | $163.62K derived: sum of 3 quarters · filed 2023-05-15 | $198.14K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $103.05K derived: sum of 2 quarters · filed 2023-03-31 | $137.56K derived: sum of 3 quarters · filed 2023-03-31 | $186.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $64.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $98.56K derived: sum of 2 quarters · filed 2022-11-14 | $147.00K 10-Q · filed 2022-11-14 | $159.66K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $34.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $82.94K 10-Q · filed 2022-08-15 | $95.61K derived: sum of 3 quarters · filed 2022-08-15 | $126.99K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $48.43K 10-Q · filed 2022-05-16 | $61.09K derived: sum of 2 quarters · filed 2022-05-16 | $92.48K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $12.66K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $44.05K derived: sum of 2 quarters · filed 2022-03-31 | $45.44K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $31.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $32.78K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.40K 10-Q · filed 2021-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |